Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

BRAFV600E in Papillary Thyroid Carcinoma Is Associated with Increased Programmed Death Ligand 1 Expression and Suppressive Immune Cell Infiltration
Trevor E. Angell, Melissa G. Lechner, Julie K. Jang, et al.
Thyroid (2014) Vol. 24, Iss. 9, pp. 1385-1393
Open Access | Times Cited: 119

Showing 1-25 of 119 citing articles:

A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors
Jeroen de Filette, Corina Andreescu, Filip Cools, et al.
Hormone and Metabolic Research (2019) Vol. 51, Iss. 03, pp. 145-156
Open Access | Times Cited: 286
Novel targeted therapies and immunotherapy for advanced thyroid cancers
George E. Naoum, Michael Morkos, Brian W. Kim, et al.
Molecular Cancer (2018) Vol. 17, Iss. 1
Open Access | Times Cited: 207
Immune and Inflammatory Cells in Thyroid Cancer Microenvironment
Silvia Martina Ferrari, Poupak Fallahi, Maria Rosaria Galdiero, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 18, pp. 4413-4413
Open Access | Times Cited: 185
Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer
Jill J. Bastman, Hilary S. Serracino, Yuwen Zhu, et al.
The Journal of Clinical Endocrinology & Metabolism (2016) Vol. 101, Iss. 7, pp. 2863-2873
Open Access | Times Cited: 152
Comprehensive screening for PD-L1 expression in thyroid cancer
Soomin Ahn, Tae Hyuk Kim, Sun Wook Kim, et al.
Endocrine Related Cancer (2017) Vol. 24, Iss. 2, pp. 97-106
Open Access | Times Cited: 143
MHC Class I Loss Is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer That Is Reversed by Interferon and Selumetinib TreatmentIn Vitro
Trevor E. Angell, Melissa G. Lechner, Julie K. Jang, et al.
Clinical Cancer Research (2014) Vol. 20, Iss. 23, pp. 6034-6044
Open Access | Times Cited: 134
Molecular pathology of thyroid tumours of follicular cells: a review of genetic alterations and their clinicopathological relevance
Giorgia Acquaviva, Michela Visani, Andrea Repaci, et al.
Histopathology (2017) Vol. 72, Iss. 1, pp. 6-31
Open Access | Times Cited: 130
Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies
Mohamed Aashiq, Deborah A. Silverman, Shorook Na’ara, et al.
Cancers (2019) Vol. 11, Iss. 9, pp. 1382-1382
Open Access | Times Cited: 125
Emerging BRAF Mutations in Cancer Progression and Their Possible Effects on Transcriptional Networks
Magdalena Śmiech, Paweł Leszczyński, Hidetoshi Kono, et al.
Genes (2020) Vol. 11, Iss. 11, pp. 1342-1342
Open Access | Times Cited: 122
Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study
Ashish V. Chintakuntlawar, Kandelaria M. Rumilla, Carin Y. Smith, et al.
The Journal of Clinical Endocrinology & Metabolism (2017) Vol. 102, Iss. 6, pp. 1943-1950
Open Access | Times Cited: 114
The immune network in thyroid cancer
Maria Rosaria Galdiero, Gilda Varricchi, Gianni Marone
OncoImmunology (2016) Vol. 5, Iss. 6, pp. e1168556-e1168556
Open Access | Times Cited: 113
Associations between BRAFV600E and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis
Chunping Liu, Tianwen Chen, Zeming Liu
World Journal of Surgical Oncology (2016) Vol. 14, Iss. 1
Open Access | Times Cited: 112
Patient Age–Associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid Cancer
Xiaopei Shen, Guangwu Zhu, Rengyun Liu, et al.
Journal of Clinical Oncology (2017) Vol. 36, Iss. 5, pp. 438-445
Open Access | Times Cited: 107
Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer
Eran Brauner, Viswanath Gunda, Pierre Vanden Borre, et al.
Oncotarget (2016) Vol. 7, Iss. 13, pp. 17194-17211
Open Access | Times Cited: 95
Long non-coding RNA NEAT1 promotes malignant progression of thyroid carcinoma by regulating miRNA-214
Jianhua Li, Suqin Zhang, Xing-Guang Qiu, et al.
International Journal of Oncology (2016) Vol. 50, Iss. 2, pp. 708-716
Open Access | Times Cited: 91
Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer
Viswanath Gunda, Benjamin J. Gigliotti, Dorothy Ndishabandi, et al.
British Journal of Cancer (2018) Vol. 119, Iss. 10, pp. 1223-1232
Open Access | Times Cited: 91
The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition
Gilda Varricchi, Stefania Loffredo, Giancarlo Marone, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 16, pp. 3934-3934
Open Access | Times Cited: 89
Immune landscape of papillary thyroid cancer and immunotherapeutic implications
Kwon Joong Na, Hongyoon Choi
Endocrine Related Cancer (2018) Vol. 25, Iss. 5, pp. 523-531
Open Access | Times Cited: 87
Immune Landscape of Thyroid Cancers: New Insights
Elisa Menicali, Martina Guzzetti, Silvia Morelli, et al.
Frontiers in Endocrinology (2021) Vol. 11
Open Access | Times Cited: 60
Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors
Peitao Zhang, Haixia Guan, Shukai Yuan, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 52
Pathogenesis of cancers derived from thyroid follicular cells
James A. Fagin, Gnana P. Krishnamoorthy, Iñigo Landa
Nature reviews. Cancer (2023) Vol. 23, Iss. 9, pp. 631-650
Open Access | Times Cited: 29
A computational approach to assessing the prognostic implications of BRAF and RAS mutations in patients with papillary thyroid carcinoma
Tahereh Haghzad, Babak Khorsand, S. Adeleh Razavi, et al.
Endocrine (2024)
Closed Access | Times Cited: 9
Leveraging the immune system to treat advanced thyroid cancers
Jena D. French, Keith C. Bible, Christine Spitzweg, et al.
The Lancet Diabetes & Endocrinology (2016) Vol. 5, Iss. 6, pp. 469-481
Closed Access | Times Cited: 69
Immunotherapy for advanced thyroid cancers — rationale, current advances and future strategies
Jena D. French
Nature Reviews Endocrinology (2020) Vol. 16, Iss. 11, pp. 629-641
Closed Access | Times Cited: 60
The Genomic Landscape of Thyroid Cancer Tumourigenesis and Implications for Immunotherapy
Amandeep Singh, Jeehoon Ham, Joseph W. Po, et al.
Cells (2021) Vol. 10, Iss. 5, pp. 1082-1082
Open Access | Times Cited: 49
Page 1 - Next Page

Scroll to top